rel-Latanoprost acid 

rel-Latanoprost acid is a relative configuration of Latanoprost acid (HY-113756A). Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor^[1]. Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes^[1][2].

Latanoprost acid (10-20 μM;24 h) reduces he protein expressions of c-fos and NFATc1^[1].
Latanoprost acid (10μM with 50ng/ml RANKL) significantly inhibits ERK, p38, AKT and JNK^[1].
Latanoprost acid (10-20 μM) significantly inhibits the mature osteoclast formation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Latanoprost acid (20 mg/kg; i.p.; once a day for 7 days) notably prevents LPS (HY-D1056)-induced bone destruction^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

390.51

C₂₃H₃₄O₅

2699713-95-4

OC(CCC/C=C/C[C@@H]1[C@H]([C@@H](C[C@@H]1O)O)CC[C@@H](O)CCC2=CC=CC=C2)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Weinreb RN, et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S53-64.  [Content Brief]

  [2]. Xu X, et al. The prevention of latanoprost on osteoclastgenesis in vitro and lipopolysaccharide-induced murine calvaria osteolysis in vivo. J Cell Biochem. 2018 Jun;119(6):4680-4691.  [Content Brief]